Breast Cancer
Articles and resources on breast cancer for patients, caregivers, and family members
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer. Read More ›
A national advocacy program trains patients with metastatic breast cancer to educate the public about the special needs of patients with advanced breast cancer. Read More ›
Dr Hayes, Immediate Past President of ASCO and Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center, explains how biomarkers offer more precise treatment opportunities for patients with breast cancer. Read More ›
Musa Mayer, breast cancer survivor and advocate, was recently recognized for her 25 years of advocacy on behalf of patients with advanced breast cancer. Read Musa’s inspiring story. Read More ›
Press Releases — April 10, 2018
Hundreds of people with metastatic breast cancer and their caregivers from across the country will attend the 2018 Conference on Metastatic Breast Cancer in Philadelphia on April 20–22, 2018, hosted by Living Beyond Breast Cancer. Read More ›
Web Exclusives — April 7, 2018
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression. Read More ›
Web Exclusives — February 26, 2018
In patients with HR-positive breast cancer, a positive circulating tumor cells assay result was associated with nearly a 20-fold increased risk for recurrence of disease. Read More ›
Web Exclusives — February 26, 2018
Older women with hormone receptor–positive, HER2-negative metastatic breast cancer who are treated with a CDK4/6 inhibitor may derive benefits similar to those seen in their younger counterparts. Read More ›
Web Exclusives — February 26, 2018
Treatment with a regimen of pembrolizumab plus trastuzumab in patients with trastuzumab-resistant advanced HER2-positive breast cancer was well-tolerated and had clinical benefit in those whose tumors were positive for a biomarker for pembrolizumab. Read More ›
Web Exclusives — February 26, 2018
Patients under age 40 with breast cancer who underwent axillary lymph node dissection were more likely to experience arm swelling and decreased range of arm motion than patients who received less invasive sentinel lymph node biopsies. Read More ›